Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | C5 | P01031 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614861 | 1.00 | HTT (0.46) | HTTC5POLBCNR1CNR2 | |
| SCHEMBL2021382 | 0.86 | HTT (0.46) | HTTC5POLBCNR1CNR2 | |
| SCHEMBL2019586 | 0.82 | SPHK1 (0.41) | POLBMEN1KMT2AHPGD | |
| SCHEMBL16312391 | 0.81 | POLB (0.45) | HTTPOLBMAPTMEN1KMT2A | |
| SCHEMBL2023567 | 0.80 | L3MBTL1 (0.42) | HTTGAAALDH1A1 | |
| SCHEMBL2017490 | 0.77 | MGLL (0.44) | MAPTGAAALDH1A1HPGD | |
| SCHEMBL2018351 | 0.75 | CNR2 (0.46) | CNR1CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL31193361 | 0.75 | CNR2 (0.46) | CNR1CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL31193427 | 0.71 | CNR1 (0.46) | CNR1CNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL2019737 | 0.71 | CNR1 (0.46) | CNR1CNR2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | claimed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | claimed |
| US-12351601-B2 | Method for producing peptide continuously | AJINOMOTO CO., INC. (JP) | 2025-07-08 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | AJINOMOTO CO., INC. (JP) | 2022-02-10 | — | — | US | disclosed |
| US-9334302-B2 | Method for removing FMOC group | AJINOMOTO CO., INC. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9206230-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140371424-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | AJINOMOTO CO., INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | HTT 2482/4885C5 3529/4885POLB 172/4885 |
| US-20220041648-A1 | METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY | VIP, NPPA, NGLY1 | HTT 2124/4885C5 1122/4885POLB 101/4885 |
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | HTT 406/4885C5 426/4885POLB 3366/4885 |
| US-20140371424-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | HTT 406/4885C5 426/4885POLB 3366/4885 |
| US-20140296483-A1 | METHOD FOR REMOVING FMOC GROUP | ESD, HM13, FURIN | HTT 781/4885C5 483/4885POLB 3678/4885 |
| US-12351601-B2 | Method for producing peptide continuously | VIP, NPPA, NGLY1 | HTT 2124/4885C5 1122/4885POLB 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.